Optimizing Treatment Regimes to Hinder Antiviral Resistance in Influenza across Time Scales

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Patterson Lomba, Oscar ^a   Althouse, Benjamin M ^b   Goerg, Georg M ^c   Hébert Dufresne, Laurent ^d  

^a ARIZONA STATE UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; COMPARTMENT MODEL; EPIDEMIC; INFLUENZA; INFLUENZA VIRUS; MATHEMATICAL MODEL; TIME; TREATMENT OUTCOME; VIRUS STRAIN; VIRUS TRANSMISSION; WILD TYPE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENDEMIC DISEASES; EVOLUTION, MOLECULAR; HUMANS; INFLUENZA, HUMAN; MODELS, STATISTICAL; ORTHOMYXOVIRIDAE; PANDEMICS; TIME FACTORS;

EID: 84875513987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059529     Document Type: Article

References (42)

1. Ferguson N, Galvani A, Bush R, (2003) Ecological and immunological determinants of influenza evolution. Nature 422: 428-433.
2. Bedford T, Rambaut A, Pascual M, (2012) Canalization of the evolutionary trajectory of the human influenza virus. BMC biology 10: 38.
3. Ferguson N, Cummings D, Cauchemez S, Fraser C, Riley S, et al. (2005) Strategies for containing an emerging influenza pandemic in southeast asia. Nature 437: 209-214.
4. Nelson M, Holmes E, (2007) The evolution of epidemic influenza. Nature reviews genetics 8: 196-205.
5. Jaberi-Douraki M, Hefffernan J, Wu J, Moghadas S (2012) Optimal treatment profile during an influenza epidemic. Differential Equations and Dynamical Systems: 1-16.
6. Moghadas S, (2008) Management of drug resistance in the population: influenza as a case study. Proceedings of the Royal Society B: Biological Sciences 275: 1163-1169.
7. Alexander M, Bowman C, Feng Z, Gardam M, Moghadas S, et al. (2007) Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proceedings of the Royal Society B: Biological Sciences 274: 1675-1684.
8. Regoes R, Bonhoeffer S, (2006) Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312: 389-391.
9. Weinstock DM, Zuccotti G, (2009) The evolution of influenza resistance and treatment. JAMA 301: 1066-9.
10. Levin B, Lipsitch M, Bonhoeffer S, (1999) Population biology, evolution, and infectious disease: convergence and synthesis. Science 283: 806-809.
11. Lipsitch M, Plotkin JB, Simonsen L, Bloom B, (2012) Evolution, safety, and highly pathogenic influenza viruses. Science 336: 1529-31.
12. Herfst S, Schrauwen EJA, Linster M, Chutinimitkul S, de Wit E, et al. (2012) Airborne transmission of influenza a/h5n1 virus between ferrets. Science 336: 1534-41.
13. Russell CA, Fonville JM, Brown AEX, Burke DF, Smith DL, et al. (2012) The potential for respiratory droplet-transmissible a/h5n1 influenza virus to evolve in a mammalian host. Science 336: 1541-7.
14. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental adaptation of an influenza h5 ha confers respiratory droplet transmission to a reassortant h5 ha/h1n1 virus in ferrets. Nature 486: 420-8.
15. Althouse BM, Bergstrom TC, Bergstrom CT, (2010) A public choice framework for controlling transmissible and evolving diseases. Proc Natl Acad Sci U S A 107Suppl 1: 1696-701.
16. Ferguson N, Cummings D, Fraser C, Cajka J, Cooley P, et al. (2006) Strategies for mitigating an influenza pandemic. Nature 442: 448-452.
17. Lipsitch M, Cohen T, Murray M, Levin BR, (2007) Antiviral resistance and the control of pandemic influenza. PLoS Medicine 4: e15.
18. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S, (2009) Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 6: e1000085.
19. zur Wiesch P, Kouyos R, Engelstädter J, Regoes R, Bonhoeffer S, (2011) Population biological principles of drug-resistance evolution in infectious diseases. The Lancet infectious diseases 11: 236-247.
20. Lipsitch M, Bergstrom CT, Levin BR, (2000) The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci U S A 97: 1938-43.
21. Keeling MJ, Rohani P (2008) Modeling Infectious Diseases in Humans and Animals. Princeton University Press.
22. Althouse BM, Patterson-Lomba O, Goerg GM, Hébert-Dufresne L, (2013) The timing and targeting of treatment in influenza pandemics inuences the emergence of resistance in structured populations. PLoS Computational Biology 9(2): e1002912.
23. Schwartz B, Bell DM, Hughes JM, (1997) Preventing the emergence of antimicrobial resistance. a call for action by clinicians, public health officials, and patients. JAMA 278: 944-5.
24. WHO (2006) Who rapid advice guidelines on pharmacological management of humans infected with avian influenza a (h5n1) virus. Technical report,World Health Organization.
25. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, et al. (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the advisory committee on immunization practices (acip). MMWR Recomm Rep 60: 1-24.
26. Qiu Z, Feng Z, (2010) Transmission dynamics of an influenza model with vaccination and antiviral treatment. Bulletin of mathematical biology 72: 1-33.
27. Lipsitch M, (2001) The rise and fall of antimicrobial resistance. Trends Microbiol 9: 438-44.
28. Handel A, Regoes R, Antia R, (2006) The role of compensatory mutations in the emergence of drug resistance. PLoS computational biology 2: e137.
29. Anderson R, May R (1992) Infectious Diseases of Humans: Dynamics and Control (Part 1, Chapters 4-7). Oxford Science Publications. Oxford University Press.
30. Lee N, Chan PKS, Hui DSC, Rainer TH, Wong E, et al. (2009) Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 200: 492-500.
31. Ling LM, Chow AL, Lye DC, Tan AS, Krishnan P, et al. (2010) Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza a (h1n1) virus infection. Clin Infect Dis 50: 963-9.
32. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. neuraminidase inhibitor flu treatment investigator group. Lancet 355: 1845-50.
33. Van den Driessche P, Watmough J, (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Mathematical Biosciences 180: 29-48.
34. Strogatz SH (1994) Nonlinear dynamics and Chaos: with applications to physics, biology, chemistry, and engineering. Addison-Wesley Pub.
35. Longini I, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, et al. (2005) Containing pandemic influenza at the source. Science 309: 1083-1087.
36. Pastor-Satorras R, Vespignani A, (2001) Epidemic spreading in scale-free networks. Phys Rev Lett 86: 3200-3.
37. Read JM, Keeling MJ, (2003) Disease evolution on networks: the role of contact structure. Proc Biol Sci 270: 699-708.
38. Barabasi AL, Albert R, (1999) Emergence of scaling in random networks. Science 286: 509-12.
39. Newman MEJ, (2002) Spread of epidemic disease on networks. Phys Rev E Stat Nonlin Soft Matter Phys 66: 016128.
40. Newman M (2010) Networks: an introduction. Oxford University Press, Inc.
41. Hansen E, Day T, (2011) Optimal antiviral treatment strategies and the effects of resistance. Proc Biol Sci 278: 1082-9.
42. Moghadas S, Bowman C, Röst G, Wu J, (2008) Population-wide emergence of antiviral resistance during pandemic influenza. PLoS One 3: e1839.